PLUTO - Prevention of CKD progression in type 1 diabetes with Long term Use of SGLTi avoiding kidney hypOxia
Phase 1
- Conditions
- Type 1 Diabetes Mellitus with chronic kidney complicationsTherapeutic area: Phenomena and Processes [G] - Metabolism [G03]Therapeutic area: Diseases [C] - Hormonal diseases [C19]Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
- Registration Number
- CTIS2023-509450-55-01
- Lead Sponsor
- Steno Diabetes Center Copenhagen
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 69
Inclusion Criteria
Adults with type 1 diabetes mellitus, Chronic Kidney Disease and albuminuria
Exclusion Criteria
Non-diabetic Kidney Disease, eGFR<25mL/min/1.73m^2, dialysis or kidney transplantation, Previous diabetic ketoacidosis, except at debut, Receiving therapy with an SGLT inhibitor within 8 weeks prior to enrolment or previous intolerence of an SGLT inhibitor.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method